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ABSTRACT Duchenne muscular dystrophy (DMD) is
the most common, lethal genetic disorder of children.
A number of animal models of muscular dystrophy
exist, but the most effective model for characterizing
the structural and functional properties of dystrophin
and therapeutic interventions has been the mdx mouse.
Despite the 20 years of investigations of the mdx
mouse, the impact of the disease on the life span ofmdx
mice and the cause of death remain unresolved. Con-
sequently, a life span study of the mdx mouse was
designed that included cohorts of male and female mdx
and wild-type C57BL/10 mice housed under specific
pathogen-free conditions with deaths restricted to nat-
ural causes and with examination of the carcasses for
pathology. Compared with wild-type mice, both mdx
male and female mice had reduced life spans and
displayed a progressively dystrophic muscle histopa-
thology. Surprisingly, old mdx mice were prone to
develop muscle tumors that resembled the human form
of alveolar rhabdomyosarcoma, a cancer associated
with poor prognosis. Rhabdomyosarcomas have not
been observed previously in nontransgenic mice. The
results substantiate the mdx mouse as an important
model system for studies of the pathogenesis of and
potential remedies for DMD.—Chamberlain, J. S.,
Metzger, J., Reyes, M., Townsend, D., Faulkner, J. A.
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As described by many investigators of Duchenne
muscular dystrophy (DMD) over the years, DMD is the
most common and lethal genetic disease experienced
by humans (1). Meryon (2) was the first to describe the
symptoms of DMD, followed shortly thereafter by Du-
chenne’s report of 13 cases of “paralysie musculaire
pseudohypertrophique,” a description based on the
transient hypertrophy of the calf muscles of boys in the
early stages of the disease that was followed by a
progressive and rapid deterioration of the muscles (3).
DMD is a recessive, X-linked disorder caused by muta-
tions in the gene that encodes the 427 kDa cytoskeletal
protein dystrophin (4). The gene is expressed in skel-
etal, cardiac, and smooth muscle (5, 6). In muscle,
dystrophin plays a critical role by connecting F-actin in
the subsarcolemmal cytoskeleton to the dystrophin-
glycoprotein (DGC) complex that spans the sarco-
lemma and attaches to laminin-2 (merosin) in the
extracellular matrix (7). Despite identification of the
precise anatomical connections of the DGC, a clarifica-
tion of the actual function of the complex has not been
established definitively. The most long-standing hy-
pothesis as to the underlying cause of the progression
of the disease (1) and still popular currently (7–13) is
that muscular dystrophy causes a structural and/or
functional defect in the plasma membrane of skeletal
muscle fibers. The hypothesis has evolved slightly to
include stabilization of the membrane particularly dur-
ing contractions (7, 10, 11).
Boys with DMD are difficult to diagnose during the
first few years of life, but early symptoms are of a
pseudo-hypertrophy, particularly of the calf muscles,
followed by an early onset of muscle wasting that
appears at  4 years of age (1). The pseudo-hypertro-
phy results from damage to muscle fibers with subse-
quent necrosis of fibers, but some regeneration of
fibers through activation of satellite cells. The process
of degeneration and regeneration produces a larger,
but much weaker muscle, hence the term “pseudo-
hypertrophy.” The muscle wasting follows as the degen-
erative process overwhelms the capability of the muscle
for regeneration. A loss of ambulation occurs between
the ages of 8 and 11, years, with subsequent confine-
ment to a wheelchair. Boys with DMD generally die
during their late teens to early 20s due to either
respiratory or cardiac failure (1, 14). Thus, DMD is a
progressive and fatal disease of muscle degeneration
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that occurs with an approximate frequency of 1 in 3500
live male births worldwide (14). As early as the 1950s, a
gradual reduction in the incidence of DMD was re-
ported, likely due to genetic counseling, then the
introduction of carrier detection in the mid-1960s, and
subsequently antenatal gender determination (15).
A great deal of what is known about dystrophin
structure-function and the pathogenesis of DMD has
come from studies of a variety of dystrophin-deficient
animals (8, 16–18), but by far the most prolific model
has been the mdx mouse, first described in 1984 (19).
The dystrophic-like symptoms in the mouse arose from
a spontaneous, nonsense mutation in exon 23 of the
dystrophin gene (18). For mdx mice, limb skeletal
muscles display degeneration and regeneration with
the associated pseudo- or compensatory hypertrophy
(20) also observed in the early stages of DMD in boys
(1). The difference is that, for boys, the condition
transitions rapidly into muscle atrophy as the degener-
ative processes outdistance the regenerative processes
(1, 14). In contrast, most of the limb muscles of the mdx
mouse maintain hypertophy throughout much of their
life span, but with a considerable loss in specific force
and normalized power (20). Compared with the muscle
wasting and degeneration observed for boys with DMD,
the diaphragm muscle of mdx mice most closely approx-
imates the age-related decline in the mass, maximum
specific force and maximum normalized power (21–24).
McCully and Faulkner (25) demonstrated that contrac-
tion-induced injury occurred only with lengthening con-
tractions, and a number of investigators have demon-
strated that, under well-controlled conditions, the skeletal
muscles of mdx mice show a marked susceptibility to
lengthening contraction-mediated force decrements (26–
32). Progressive histopathology and contractile dysfunc-
tion are also evident in cardiac muscles of the mdx mouse
(33–36). Acute heart failure is also evident in the mdx
mouse on cardiac stress testing (35).
The structural and functional properties of the skel-
etal muscles of mdx mice have undergone extensive
investigation over the past 30 years (21, 37–44) and a
wide variety of genetic interventions have utilized the
mdx mouse model (reviewed in ref. 8, 45). In particular,
dystrophin replacement in muscles of mdx mice, either
via germ-line insertion in transgenic animals or after
delivery to adults using viral vectors, has demonstrated
the possibility of a therapy for DMD using gene therapy
(22, 46–48). Despite the diversity of the structural and
functional studies and sophistication of the genetic
interventions, the inter-relationships between muscle
structure and function with age throughout the life
span of the mdx mouse have only recently been appre-
ciated (20, 23, 49), and very few genetic studies have
focused on the effect of the age of the mice (50).
Furthermore, although interesting, none of these stud-
ies have resolved the issue as to whether the absence of
dystrophin and the impaired structure and function of
the diaphragm and the heart affect the life span of the
mdx mouse.
A previous study attempted to establish, under con-
ventional housing conditions, the consequences of
dystrophin deficiency on the survival of mdx mice (42,
51), but by 18 months mdx mice had difficulty groom-
ing and obtaining food and water unaided, and the last
mdx mouse died at 24 months. These observations were
inconsistent with our studies that examined groups of
six mdx mice for up to 28 months of age (20). To
resolve the issue, for the first time a true life span study
of the mdx mouse was designed under specific patho-
gen-free housing conditions for cohorts of male and
female mdx and C57Bl/10 wild-type mice, with deaths
restricted to natural causes. The hypothesis was tested
that, compared with wild-type mice, the absence of
dystrophin in the striated muscles of mdx mice shortens
the life span. The results validate the previous observa-
tions of the status of the mdx mouse as a highly effective
model system in which to pursue the underlying patho-
logical mechanisms of DMD disease, causes of the
shortened life span, and potential therapeutics for
remediation of DMD.
MATERIALS AND METHODS
Animals
Breeding colonies for this study were initially purchased from
The Jackson Laboratory (Bar Harbor, ME, USA). The breed-
ing pairs consisted of wild-type mice (C57BL/10ScSn/J) and
mdx mice (C57BL/10ScSn-Dmdmdx/J) and were housed in a
specific pathogen-free barrier facility at the University of
Michigan. Litters of mice were weaned at 3 wk of age and
separated into cages of male or female mice. To monitor life
spans, 83 wild-type mice (38 male and 45 female) and 94 mdx
mice (47 male and 47 female) were monitored daily after
weaning. Dates were recorded for all mice that died sponta-
neously during the study. In other cases, mice that showed
signs of distress such as visible tumors, listlessness, or that
stopped eating and were deemed close to death, were sacri-
ficed and the veterinary staff performed a necropsy on the
carcass. Veterinary care for the mice was provided by the
University of Michigan Unit for Laboratory Animal Medicine
(ULAM) faculty members and veterinary residents. All proto-
cols were performed in accordance with the guidelines of the
University of Michigan’s Committee on the Use and Care of
Animals and the USPHS Guide for the Care and Use of Laboratory
Animals (DHHS Pub. No. 85–23 (NIH), Revised 1985, Office
of Science and Health reports, Bethesda, MD, USA). The
mice were housed up to four mice per cage in cages with
microisolator lids and 1/8 Bed-O-Cobs bedding (The Ander-
sons, Maumee, OH, USA). Equal 12 h light/dark cycles were
maintained with the changeover at 8 AM and 8 PM. The mice
were fed ad libitum with Purina Laboratory Rodent Diet 5001
(PMI Nutrition International, St. Louis, MO, USA).
Life span analysis/necropsy
The status of the mdx and wild-type mice entered in the “Life
span Study” were monitored by ULAM caretakers at least
twice a day. Mice that appeared at risk were monitored even
more frequently. The vast majority of the mice in each of the
four groups, male and female and mdx and wild-type, died of
natural causes and were found dead in their cages. Ten mice
were diagnosed with life-threatening tumors or conditions
that the pathologist deemed warranted euthanasia. Cage
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cards were maintained for each mouse in each cage, with the
date of birth registered; at the time of death, the date of the
death was cited and the age in months and days was calcu-
lated. When the cause of death was known, the cause was
recorded on the cage card. Carcasses were examined by a
veterinarian pathologist, and tumors or abnormal growths
were dissected from the carcass and prepared for the appro-
priate analyses.
Muscle histology
For analysis of muscle morphology, the heart, tibialis anterior,
extensor digitorum longus, quadriceps, soleus, diaphragm,
tongue, and gastrocnemius muscles were excised rapidly after
sacrifice, coated in Optimal Cutting Temperature (O.C.T;
Sakura Finetek, Torrance, CA, USA) and frozen in liquid
nitrogen-cooled isopentane. Serial cryosections of 5 m thick-
ness that had equilibrated to room temperature were stained
with hematoxylin and eosin-phloxine (H&E). Coverslips were
positioned on the slides and attached using a drop of
Permount (Fischer Scientific, Hampton, NY, USA) and dried
at room temperature overnight before viewing under a light
microscope. Brightfield photographs were taken using a
Nikon E1000 microscope (Melville, NY, USA) and a SPOT-2
camera system (Diagnostic Instruments, Sterling Heights,
MI, USA).
Tumor immunohistochemistry
Tumors were excised from the underlying skeletal muscle
mass and frozen cryosections were prepared as described in
the previous section. Sections were incubated with antibodies
against MyoD, Pax7, desmin, and myogenin (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Immunohistochemis-
try was performed using the Vectastain ABC kit (Vector
Laboratories, Burlingame CA, USA). Briefly, tissue was fixed
with cold methanol for 2 min. Slides were incubated with
blocking solution (1% Tween-20, 3% BSA, 2% gelatin in PBS)
for 30 min, followed by primary antibody [MyoD, myogenin,
and Pax7 (1:400), desmin (1:100)] for 30 min, then biotin-
labeled secondary antibody (Vector Laboratories, Burlin-
game CA, USA) for another 30 min, streptavidin-horseradish
peroxidase (Vector Laboratories, Burlingame CA, USA) for
15 min, and AEC (3-amino-9-ethylcarbazole) (Sigma, St.
Louis, MO, USA) substrate for 10 min, which produces an
insoluble end product that is red in color. Slides were washed
three times for 5 min with PBS and 1% BSA between
incubations. Photography was as described in the previous
section.
RESULTS
Longevity of mdx and wild-type mice
Compared with the longevity of wild-type mice, the
longevity of the mdx mice was reduced substantially
(Fig. 1A). The first male and female mdx mice began to
die at 14 months of age whereas the wild-type mice did
not begin to die until 18 months (males) and 20
months (females). The longest lived of the mdx mice
died at 28 months, whereas the longest lived wild-type
mouse survived until 36 months. For average life span,
female wild-type mice lived 27.0 months and male
wild-type mice lived 26.5 months (Fig. 1B). In contrast,
the average life span for female mdx mice was 22.5
months and for male mdx mice 21.5 months (Fig. 1B).
These numbers represent a 17% reduction in life span
for female mdx mice and a 19% reduction for male mdx
mice.
Morphological analysis of muscles
Because significant histopathological abnormalities
were observed in both the diaphragm and heart mus-
cles of the old mdx mice, a reasonable assumption is
that their reduced life span resulted primarily from
respiratory and/or cardiac failure, as has been observed
in boys with DMD (14, 52). The obvious exceptions
were the mice that developed tumors (see below). The
diaphragm muscle has been described as the most
severely affected muscle in the mdx mouse (23, 24). In
young mdx mice, the diaphragm muscles display rela-
tively little inflammation compared with that evidenced
in diaphragm muscles of 26 months of age mdx mice,
and none was observed in wild-type diaphragms at 24
months (Fig. 2). For both old, 26 months of age, male
and female mdx mice, the diaphragm muscle displayed
Figure 1. Life span analysis for wild-type and mdx male and
female mice. Graphs showing the age at death for the female
(A) and male (B) mice. Circles denote the age at which each
animal died. C) Histogram showing the average age at death
of male and female wild-type (C57BL/10) and mdx mice. The
average life span between wild-type and mdx males and
between wild-type and mdx females was highly significant, as
shown.
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a large degree of fibrotic infiltration and loss of muscle
fibers (Fig. 2C). Surprisingly, the most severely affected
muscle other than the diaphragm was the tongue, a
muscle that has not been studied extensively in the mdx
mouse. The fibrosis and loss of muscle fibers were
particularly severe in the central portion of the tongue
(Fig. 3). The hearts of old mdx mice displayed frequent
scattered areas of fibrotic lesions and mononuclear cell
infiltration (Fig. 4). The lesions were characterized by
scattered fibrosis, with no suggestion of any regional
specificity in the occurrence of the lesions.
As expected from the extensive histochemical and
histological studies that have focused on the limb
muscles of young mdx mice (37, 39, 42, 51, 53, 54), the
limb muscles display the characteristic features of dys-
trophic muscle pathology. For young mdx, compared
with age-matched wild-type mice, extensive morpholog-
ical and functional differences have been described in
detail (for references see above). Furthermore, the
maximum force and power of soleus and extensor
digitorum longus (EDL) muscles have been compared
for mdx and wild-type mice from 6 to 26 months of age
(20). In contrast, the dramatic increase in the degree of
morphological abnormalities in the skeletal muscles of
old compared with young mdx mice have not been
reported. These abnormalities include increased necro-
sis, fibrosis, and accumulation of adipocytes. Represen-
tative photographs of skeletal muscles from a 24-
month-old wild-type mouse are displayed in Fig. 5A, B
and from 4-, 6-, and 26-month-old mdx mice in Fig.
5C–H. The photographs were of muscles obtained from
mice that were sacrificed while in good health and from
mice that were not a part of the life span study shown in
Fig. 1. As expected, the 24 month wild-type muscles
displayed no morphological abnormalities. In contrast,
the mdx mice displayed typical dystrophic features at
each age examined. The dystrophic features included
centrally located myofibers, necrotic fibers, small cali-
ber regenerating fibers, moderate amounts of fibrosis,
and some fatty infiltration. All skeletal muscles exam-
Figure 2. Histology of wild-type and mdx mouse diaphragm
muscles. Diaphragms were excised, frozen in O.C.T., and
5 m cryosections were prepared and stained with hematox-
ylin and eosin. A) 24-month-old wild-type mouse diaphragm.
B) 4-month-old mdx mouse diaphragm. C) 26-month-old mdx
mouse diaphragm. Scale bar  250 m.
Figure 3. Montage images of the most affected nonrespiratory
muscle in old mdx mice. 5 m transverse cryosection of the
entire tongue. Scale bar: 10 m.
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ined displayed a moderate to severe degree of dystro-
phic histopathology by 26 months of age (Fig. 5C–H).
For example, note the increased necrosis fibrosis and
adipocyte accumulation in the 26 months soleus com-
pared with the same muscle group at 4 months (Fig. 5C,
D). In our experience, the soleus is the most morpho-
logically dystrophic limb muscle in the mdx mouse at
any age (Figs. 2 and 3 and data not shown).
Necropsy analysis
With the exception of clearly defined tumors (see below),
necropsy results were generally uninformative, although
one male wild-type mouse developed a suppurative pleu-
ritis and was sacrificed. Analysis of multiple tissues re-
vealed no specific findings in the wild-type mice.
Incidence of tumoregenesis
A surprising outcome of our study was the observation
that mdx mice were prone to develop sarcomas, partic-
ularly rhabdomyosarcomas. Only three of the wild-type
mice developed tumors, while tumors were found in
seven mdx mice. One wild-type and one mdx mouse,
both females, each developed a lymphosarcoma at
1.5 years of age. Two additional male wild-type mice
developed sarcomas by 30 months of age: one an
osteosarcoma, and the other a hemangiosarcoma. In
contrast, 6 of the 94 mdx mice developed rhabdomyo-
sarcomas, an extremely rare tumor in mice (55). These
tumors were found in three male and three female
animals. The average age at which the rhabdomyosar-
comas were detected was 20 months, with a range
between 16.5 and 24 months. No rhabdomyosarcomas
were observed in any wild-type mice.
Three tumors were analyzed further to obtain details
on the nature of the rhabdomyosarcoma. Low power
imaging of one tumor showed normal skeletal muscle
connected to a large mass of tightly packed small cells
interspersed with larger, often multinucleated cells
displaying occasional cross striations (Fig. 6A). A sec-
ond tumor imaged at higher magnification (Fig. 6B)
showed randomly arranged eosinophilic cells with con-
siderable variation in cell size and shape, including
small, round tumor cells with hyperchromatic nuclei
and large, polygonal-shaped tumor cells with abundant
eosinophilic cytoplasm, which often contain diagnostic
cross striations (inset). The histology of these tumors
was suggestive of the alveolar type of rhabdomyosar-
coma. To obtain immunological confirmation of the
tumor type, cryosections from three tumors were im-
munostained with markers of skeletal muscle myogen-
esis. As shown in Fig. 6C–F, essentially all tumor cells
were positive for myogenin and Pax7 expression
while 50% were positive for MyoD expression. The
histology combined with widespread myogenic regula-
tory gene expression is most compatible with the alve-
olar form of human rhabdomyosarcoma (55–59).
DISCUSSION
The mdx mouse is the most widely studied animal
model for Duchenne muscular dystrophy (17). These
mice carry a premature stop codon in exon 23 that
leads to the absence of detectable dystrophin except in
rare, revertant myofibers (18, 60). Most studies of
muscle pathology in mdx mice have reported that the
histopathological abnormalities are milder than in
DMD, and numerous reports have stated that the
pathology is not progressive except for the diaphragm
muscle (21, 24). Invariably, the masses of the limb
muscles of young mdx mice show a substantial hyper-
trophy of from 20% to 30% in some studies (21, 38, 41,
42) to as much as 30% to 60% in others (20, 42). As
with the pseudo-hypertrophy observed in the calf mus-
Figure 4. Histology of 20-month-old control and
mdx mouse hearts. The hearts were excised,
frozen in O.C.T., and 5 m cryosections were
prepared and stained with hematoxylin and
eosin. A, B) 20-month-old hearts from control
C57Bl/10 mice; C, D) 20-month-old hearts from
mdx mice. C, D) Asterisks denote areas of fibro-
sis. Scale bar: A, C) 100 m; B, D) 50 m.
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cles of young boys (1), the increased mass of the
muscles of the mdx mice is attributed to the ongoing
cycle of degeneration and regeneration. The damaged
fibers with impaired function result in a 25% to 35%
loss in maximum specific force (kN/m2) and normal-
ized power (W/kg), respectively (20).
Life span analyses
The studies of mdx mice have focused mainly on
comparisons of young age groups of mdx and wild-type
mice (37, 39). A few have extended the observations of
a limited number of conventionally housed mdx mice
(n14) throughout their life span (42, 51), but unfor-
tunately these mice were short-lived, with the oldest
dying at 24 months. Despite these somewhat random
observations, to date there has not been a detailed
analysis of the life spans of mdx and wild-type mice
under controlled conditions that include a specific
pathogen-free environment. Our results reveal that
muscle histopathology of the old mdx animals is more
extensive and widespread than what has been observed
in young mdx mice in all muscle groups analyzed.
Furthermore, for female and male mdx mice, a 17%
and 19% reduction in life span was observed compared
with wild-type mice of the same gender. A strikingly
high incidence of rhabdomyosarcoma was observed for
mdx mice, an otherwise extremely rare tumor in mice
(55, 58).
The question of interest is whether the observed
reduction in life span observed in mdx mice is of
general significance and thus relevant to the age-
dependent progression of the human pathology of
muscular dystrophy. A controlled life span study has
not been reported in the canine model of DMD, but
these dogs are severely affected and many die young
(16, 61). Recently, a reduced life span has also been
observed in a Drosophila model where dystrophin ex-
pression was suppressed using RNAi technology (R.
Bodmer, personal communication). These observa-
tions suggest that interference with dystrophin function
in mammals as well as in an insect model affects
Figure 5. Histology of wild-type and mdx mouse
limb muscles. The indicated muscles were ex-
cised, frozen in O.C.T., and 5 m cryosections
were prepared and stained with hematoxylin
and eosin. A) 24-month-old wild-type mouse
TA; B) 24-month-old wild-type mouse quadri-
ceps; C) 6-month-old mdx mouse TA; D) 26-
month-old mdx mouse TA; E) 4-month-old mdx
mouse soleus; F) 26-month-old mdx mouse so-
leus; G) 26-month-old mdx mouse tongue; H)
26-month-old mdx mouse quadriceps. Scale
bar  250 m.
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longevity and that this aging phenotype is likely due to
a muscle autonomous effect of dystrophin.
Impact of aging on histology
The degree of dystrophic pathology observed in the
limb muscles of old mdx mice was visibly worse than in
4- and 6-month-old mdx mice, but not nearly as exten-
sive as observed in young or old mdx diaphragm mus-
cles (21–24, 46). In contrast, the soleus and tongue
muscles of the older mdx mice displayed an extensive
dystrophic pathology intermediate in severity between
the diaphragm and quadriceps/TA muscles. The exten-
sive histopathology noted in the tongue of the mdx
mouse has not been reported previously. Muscles of the
tongue are organized in a complex pattern consisting
of longitudinal, transverse, and vertically oriented myo-
fibers (62). This critical organ is used in various ways
during normal suckling, chewing, swallowing, and
breathing. In laboratory mice, which lead a sedentary
life, the tongue and diaphragm muscles are among the
most active and continuously used, which may in part
explain the greater degree of dystrophic histopathology
relative to other skeletal muscles. While the diaphragm
and soleus are among the slowest muscles of the mouse
(43, 63), the intrinsic tongue muscles are composed
almost exclusively of fast-twitch fibers in both rats and
mice, suggesting that the degree of dystrophic pathol-
ogy in mdx mice is not a simple reflection of fiber type
composition (64–66). The severity of the pathology
suggests that the tongue muscle might be useful in the
analysis of potential therapeutic interventions.
Contractile properties of skeletal muscles of old
mdx mice
The diaphragm muscles of 4–6 months and 24 months
wild-type mice have specific forces of  225 kN/m2
(23). In contrast, the diaphragm muscle is the only
skeletal muscle of the mdx mouse to demonstrate a
progressive loss of specific force throughout the life
span (20, 23, 49). When the specific force (kN/m2) is
calculated for the total cross-sectional area (CSA) of the
diaphragm, with both viable and necrotic tissue in-
cluded, the specific force is 125 kN/m2 for a 2-month-
old mdx mouse, 95 kN/m2 for a 4- to 6-month-old, and
46 kN/m2 for a 24-month-old (49). These values are
55%, 42%, and 20% of the values for wild-type mice.
Furthermore, at 24 months of age, only 41% of the CSA
of the diaphragm muscles of mdx mice is composed of
viable skeletal muscle fibers (23). Consequently, for
24-month-old mdx mice, with a specific force of 116
kN/m2, even the force development for the viable
muscle is still greatly diminished compared with that of
age-matched wild-type mice. The present data (Fig. 2C,
D) are consistent with the magnitude of the histological
evidence of deterioration observed in the diaphragm
muscle.
Figure 6. Rhabdomyosarcomas from mdx mouse
muscles. Tumors were excised, frozen in
O.C.T., and 5 m cryosections were prepared
and processed as described below. A) Low
power image of a tumor stained with hematox-
ylin and eosin. A section of the underlying
skeletal muscle layer is visible in the lower left
quadrant. Note the sporadic islands of eosino-
philic striated structures. Scale bar  250 m.
B) A second tumor was also sectioned and
stained with hematoxylin and eosin and photo-
graphed at higher magnification. Note the ran-
domly arranged eosinophilic cells with consid-
erable variation in cell size and shape, including
small, round tumor cells with hyperchromatic
nuclei containing prominent nucleoli. Also
present are large, polygonal-shaped tumor cells
with abundant eosinophilic cytoplasm, which
often contain diagnostic cross striations (inset).
Scale bar 50 m; inset is a 2magnification.
C–E) Frozen sections from a third tumor with
morphological features similar to those in
panel B were stained with antibodies against
various myogenic regulatory proteins. C) Stain-
ing for MyoD; D) staining for myogenin; E)
staining for Pax7; F) no primary antibody. Ap-
proximately 50% of the cells in the tumor were
positive for MyoD, while 90% stained positive
for myogenin and Pax7. Scale bar for panels
C–F is shown in panel F and represents 250 m.
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A study of structure-function relationships of the
EDL and soleus muscles of male mdx compared with
those for wild-type mice at 6, 17, 24, and 28 months of
age (23) showed that throughout the life span of mice,
although absolute values for muscle mass ranged
from 40% higher at 5 months to 20% higher at 28
months, the maximum absolute force and power
changed minimally and maximum specific force (kN/
m2) and normalized power (W/kg) were only 20%
lower (23). Unlike the minor age-related changes in
the absolute and normalized values for force and power
developed by the limb muscles, the capability of the
diaphragm muscle to develop force and power under-
goes a highly significant, almost linear age-related loss
that, by 24 months, of age may affect respiratory
function and possibly life span.
Heart function
Advances in cellular and organ-level technologies have
allowed new insight into the mechanisms of cardiac
dysfunction in mouse models of disease and aging.
Using microcarbon fiber technology, the phenotype of
single intact cardiac myocytes from mdx mice has been
described (35). The passive tension extension proper-
ties of myocytes from mdx and wild-type mice demon-
strate that during a stretch of physiologically relevant
magnitude, the dystrophin deficiency renders the cell
less compliant owing to transient increases in intracel-
lular Ca2. At a critical threshold, excessive Ca2
overload initiates irreversible hypercontracture and
death of the myocyte. At the organ-level in vivo, micro-
manometry catheters demonstrated reduced systolic
performance of the heart of the mdx mouse and
increased acute cardiac failure during cardiac stress
testing (35). These deficits in cardiac function likely
contribute significantly to the reduced life span of the
mdx mouse.
Rhabdomyosarcomas in dystrophic mice
The occurrence of spontaneous alveolar rhabdomyo-
sarcomas in dystrophic mdx mice is a striking finding
since this muscle tumor has not previously been ob-
served to arise spontaneously in mice, and it arises only
rarely after significant genetic manipulation of the
mouse genome (55, 58, 67, 68). We observed 6 rhab-
domyosarcomas in 94 mdx mice at an equal frequency
in both males and females. Of interest was the obser-
vation that no tumors were detected earlier than 16
months of age. Rhabdomyosarcoma does not appear to
be unique to mdx mice in this longevity study, as one of
our groups (Washington) observed numerous addi-
tional rhabdomyosarcomas in their mdx mouse colonies
that were not a part of the longevity study. The inci-
dence of rhabdomyosarcoma in this general colony
cannot be determined precisely, since most of the mice
were not aged extensively due to the nature of their
experimental involvements. Despite these limitations in
the experimental design, in a 1 year period we observed
23 tumors associated with skeletal muscles in our mdx
mouse colony. While most tumors were not analyzed
extensively, those that were had morphological charac-
teristics of rhabdomyosarcoma and four out of four
examined displayed widespread (90% of the tumor
cells) expression of myogenin (data not shown). The
tumors were found with approximately equal frequency
in all four limbs. We have never observed a rhabdomyo-
sarcoma in our wild-type mice, nor have any been
observed in our transgenic mdx mice expressing a
functional dystrophin (e.g., ref. 22). We have, however,
observed rhabdomyosarcomas in transgenic mdx mice
expressing nonfunctional dystrophins or other trans-
genes (e.g., ref. 8).
In humans, rhabdomyosarcoma is a malignant tumor
originating from striated muscle. Rhabdomyosarcoma
of the head and neck is primarily a disease of the first
decade of life, and it is the most common soft tissue
sarcoma observed in childhood (69). Investigators have
proposed that these tumors are derived from primitive
mesenchyme that retained its capacity for skeletal mus-
cle differentiation (70, 71). Recently, the origin of
rhabdomyosarcoma has been directly associated with
mutations within satellite cells of adult muscle (72),
and most cases are associated with the expression of a
Pax3: or Pax7:Fkhr fusion gene that has arisen by
chromosomal translocation (73). To our knowledge,
there are only two cases reported of rhabdomyosar-
coma in DMD patients—one of the alveolar form and
another of the embryonal form (74, 75). Rhabdomyo-
sarcomas may be less frequent in DMD patients than in
the mdx mouse because DMD patients rapidly lose
muscle mass and their satellite cell numbers drop
significantly as they prematurely acquire proliferative
senescence (76). As shown in Figs. 2 and 3, limb
muscles of mdx mice never lose a major proportion of
their myofiber content, suggesting a significantly more
robust ability to regenerate myofibers throughout their
life span. Also, spontaneously immortalized myoblast
lines are easily derived from mouse limb muscles,
whereas none have been successfully generated from
humans (77).
The only previous example of alveolar rhabdomyo-
sarcomas in mice was observed in transgenic animals
that conditionally expressed a Pax3:Fkhr fusion gene in
differentiating myocytes (55). Why are mdx mice
unique among all nontransgenic mice in displaying a
susceptibility to develop rhabdomyosarcoma? We spec-
ulate that the lifelong continuous myofiber degenera-
tion and regeneration that characterize this animal
model are associated with continuous and massive
activation and proliferation of satellite cells, which
greatly increases the chance of developing random and
spontaneous mutations. If the appropriate combina-
tion of mutations arise or accumulate in a satellite cell,
the progeny of the satellite cell might lead to formation
of a rhabdomyosarcoma on differentiation into a myo-
cyte, which would then be unable to complete terminal
differentiation into myotubes and myofibers. Further
analysis of the tumor cells will be required to fully
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understand this phenomenon. Despite the limitations,
our results suggest that mdx mice might be a useful
model system not only for DMD, but also to study the
origin, progression, and treatment options for alveolar
rhabdomyosarcoma. The results also raise the possibil-
ity that treatments for DMD that do not slow ongoing
myofiber necrosis and regeneration, but which lengthen
life span, could lead to an increase in the incidence of
rhabdomyosarcoma in older patients.
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